Revance Therapeutics Inc (NASDAQ:RVNC)
| 27.02 Delayed Data As of Sep 30 |  +1.35 / +5.26%Today’s Change | 11.27 Today|||52-Week Range 29.51 | +65.56% Year-to-Date |
Latest RVNC News | Press Releases
No recent news for Revance Therapeutics Inc.
Today’s Trading
| Previous close | 25.67 |
| Today’s open | 25.68 |
| Day’s range | 25.68 - 27.31 |
| Volume | 105,089 |
| Average volume (3 months) | 1,136,868 |
| Market cap | $2.0B |
Data as of 4:01pm ET, 09/30/2022
Growth & Valuation
| Earnings growth (last year) | +14.31% |
| Earnings growth (this year) | +16.44% |
| Earnings growth (next 5 years) | +192.00% |
| Revenue growth (last year) | +407.65% |
| P/E ratio | NM |
| Price/Sales | 14.16 |
| Price/Book | 26.17 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XENEXenon Pharmaceutical... | +0.20 | +0.56% |
| ---- | ||
| ISEEIVERIC bio Inc | +0.62 | +3.58% |
| ---- |
Data as of 4:02pm ET, 09/30/2022
Financials
| Next reporting date | November 3, 2022 |
| EPS forecast (this quarter) | -$0.79 |
| Annual revenue (last year) | $77.8M |
| Annual profit (last year) | -$281.3M |
| Net profit margin | -361.59% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Nashville, Tennessee |
Forecasts
